Of the available methods for adult height prodiction calculated at onset of therapy, the Tamer method based on bone age best reflects the height that probably would be attained without therapy. HGH therapy initiated a clear increase in height prediction. Androgen therapy, in addition to HGH therapy, resulted in an additional small increase in the predicted height.
Final height achieved was significantly correlated with midparent height. Final height expressed in SDS of target height, accounting for the genetic background, was significantly correlated with the bone age deficit, with height SDS-bone age (BA) at onset of therapy, and with the increase in height velocity during the first year of HGH therapy. No correlations were found between final height expressed in SDS of target height and chronologic age, height SDS-CA at onset of therapy and pretreatment height velocity.
Abbreviations BA, bone age CA, chronologic age GH, growth hormone GHD, growth hormone deficiency HGH, human growth hormone SDS, standard deviation scores SDS-CA, standard deviation scores for chronologic age SDS-BA, standard deviation scores for bone age TSH, thyroid stimulating hormone Therapy with HGH for pituitary growth failure is quite successful in most instances. It constitutes a heavy medical and financial burden and must be carried out over many years, preferably until cessation of growth. Even though the treatment has been available now for more than 20 years (8) and many publications have appeared on this subject (9), final results are only now appearing in the literature (2, 3, 13) . The final height achieved is influenced by many variables, which might be of importance for the indication and guidance of therapy. The present report is an analysis of growth variables in five girls and 13 boys with idiopathic GHD, who were treated with HGH until growth terminated. Ten of the boys also obtained androgen therapy because of additional gonadotrophin deficiency. Changes in adult height prediction were longitudinally analyzed during HGH and androgen therapy. Not only HGH but also androgen therapy proved to be beneficial with respect to final height.
PATIENTS AND METHODS
The clinical and diagnostic data of the patients were previously published (13) . None of the patients included in the present report suffered from organic hypopituitarism. Thirteen patients (I 1 males and two females) were classified as having total GHD and five patients (two males and 3 females) as having partial GHD as defined earlier (5) . Eleven of the 13 patients with total GHD had additional gonadotrophin deficiency, eight had ACTH and six TSH deficiency. All five patients with partial GHD had isolated GHD. The growth data of the patients at onset of therapy are shown in Table 1 . The diagnosis of GHD was based on plasma concentrations of growth hormone during stimulation tests (insulin, and arginine tolerance test), which were made according to our diagnostic criteria (6) . Peak values below 2 ng/ml were classified as total GHD, and peak values between 2-7 ng/ml on three repeated tests were classified as partial GHD (5). Gonadotrophin deficiency was assumed when the patient did not spontaneously enter puberty in spite of a bone age of 14 years in boys and 13 years in girls. ' Values given as mean & 1 S.D., range given in parentheses.
GHD, idiopathic growth hormone deficiency. SDS, standard deviation scores; SDS-CA, standard deviation scores for chronologic age; SDS-BA, standard deviation scores for bone age.
which adult height is expected because of the genetic background.
All height measurements were done with a Harpenden stadiometer. Height was expressed as SDS-CA and SDS-BA.
x -,
where x represents the measurement; %, the mean height at the relevant chronologic age (respective bone age); and S.D., the standard deviation. The standards for height are those of the Zurich longitudinal growth study (7) . BA was estimated by the TW2-RUS method of Tanner (12) . The SDS of bone age TW2-RUS was calculated from the published standards (12), whereby 2 S.D. were taken as the difference between the fiftieth and the third percentile. Predictions of adult height were calculated by the methods of Tanner (12) , namely the chronologic-age-based and the bone-age-based system and by the methods of Bayley-Pinneau (I), and by the one of Roche-WainerThissen (lo), which uses the bone age estimation of Greulich and Pyle (4).
The extrapolated height as an approximate estimation of the expected final height without therapy was assessed in patients with GHD and gonadotrophin deficiency by linear extrapolation of the pretreatment growth curve up to the age of their actual cessation of growth.
The HGH used for therapy during the first years was a preparation of Raben with a biologic activity of 0.9-1.8 IU per mg. Later on, a preparation of Zachmann, Zurich (extraction by Roos method) and finally Crescormon (Kabi) also extracted by the Roos method with a biologic activity of 1.2 IU per mg were used. The dosage was approximately 10-12 IU per M~ per wk in three divided intramuscular injections. The duration of therapy was 6.2 + 2.4 years (range 3.1-10.6 years). In no patient could GH antibodies be detected by radioimmunoassay. Patients with pituitary hypothyroidism were treated with 100-200 pg 1-Na-thyroxine (Eltroxin, Glaxo) per day according to the serum thyroxine level, which was measured at half yearly intervals. Only one patient received 10 mg hydrocortisone per M' per day in three doses. The male patients with gonadotrophin deficiency received testosterone injections (Triolandren, Ciba) of 100 mg for 3 months and thereafter 250 mg intramuscularly once a month or 1500 U human chorionic gonadotrophin (Pregnyl, Organon) three times per wk intramuscularly starting at the BA of approximately 14 years. The only female with gonadotrophin deficiency received 20 pg cyclical ethinylestradiol per day and 5 mg progesterone per day.
limits.
Longitudinal analysis of height and BA. A longitudinal analysis of height and bone age in males with total GHD showed a progressive improvement of the height SDS-CA during the initial 4 years of HGH therapy from -5.6 to -3.8 SDS with no influence on BA SDS (Fig. 1A) . After adding androgen therapy to induce puberty in the patients with additional gonadotrophin deficiency at a mean CA of 18.5 + 2.0 years (range 15.3-20.8 years), an increase in growth velocity from 4.7 to 6.3 cm/year was elicited (Fig. IB, top pannel) . Height SDS-CA was improved by one SDS and BA SDS advanced by 1.9 SDS.
Adult heightpredictions. In another approach to assess the effect of therapy on growth and skeletal maturation, longitudinal calculations of adult height predictions were done. Although all available prediction methods have not been designed for the estimation of final height.in pathologic conditions such as GHD, the changes in prediction supposedly reflect the integrated change of longitudinal growth and skeletal maturation. An improvement in prediction would mean that growth over a certain period was high compared to BA progression. The four available methods for adult height prediction calculated at onset of therapy gave quite divergent results (Table 3 ). The Bayley-Pinneau method mirrored the height that was achieved with therapy, whereas the Tanner method based on bone age reflects the height that probably would have been attained without therapy, i.e., the extrapolated height. The Tanner method based on bone age is therefore best suited for our purpose, namely to continuously assess the effect of therapy on growth. The increase in height prediction with therapy over the predicted values at onset of therapy is depicted in Figure 2 . HGH therapy initiated a clear increase in height prediction ( Fig.  2A) . Androgen therapy gave a further increase in the height prediction (paired t test: P < 0.02) (Fig. 2B) .
The six patients with TSH deficiency supplemented with thyroxine reached final heights that were not different from those without TSH deficiency (mean final height as SDS of target height: -1.78 versus -1.84).
Correlations offinal height to growth variables at onset of therapy. These values were calculated in order to analyze the possible factors influencing final height. Final height was found to significantly correlate with midparental height ( r = 0.67, p < 0.01). In order to account for this genetic factor, all furthe; correlations were calculated as final height expressed in SDS of target height with respect to growth variables at onset of therapy. Significant correlations were found with BA ( r = -0.5 1, P < 0.05), with bone age SDS, with height SDS-BA, and with the increase in height velocity during the first year of HGH therapy (Fig. 3) . The more retarded the BA and the less severe the height deficit with respect to the BA and the greater the growth response at onset of HGH therapy, the better was the final result. No correlations were found between final height and pretreatment height velocity, height SDS-CA and chronologic age at onset of therapy. their patients would fmally reach a height within normal limits. In spite of a very heavy fmancial burden and laborious longterm therapy by approximately 1000 intramuscular injections per patient almost half of them do not reach a fully satisfactory adult height. A retrospective analysis of the possible factors compromising an acceptable final height seems highly warranted.
Prognostically more important than Chronologic Age is Bone Age at time of onset of therapy. A large height deficit does not adversely affect final height if BA delay is of similar extent. The relatively late diagnosis resulting in severe height deficits in most of our patients with respect to their BA probably is an important factor for the relatively high percentage of unsatisfactory results. Nowadays, the diagnosis is made much earlier in most cases, Tanner, CA-based4 149.2 f 6.9
( P < 0.01)3 ( P < 0.01)3
Tanner, BA-based4 132.6 + 15.6 ( P < 0.01)3 n.s.
Paired t test for statistical analysis and n.s., not significant.
.
Significant.
CA, chronologic age and BA, bone age. which will hopefully lead to better final results. The significant correlation between the final height and the delay in bone maturation is a strong indication that anabolic steroids should not be given during the early phases of hormonal therapy because of the risk of disproportionate acceleration of bone maturation. In the early phase of therapy height is strongly increased by HGH therapy without disproportionally accelerating bone maturation, thereby markedly improving fmal height prediction. The first year's response to HGH therapy is of prognostic value in our experience in contrast to the findings of Burns et al. (2) .
The mean CA at onset of androgen therapy was 18.5 k 2.0 years. In the patients in the study by Burns et al. .. even later, namely at a mean CA of 20.4 years. The delay in our patients was due to the marked retardation of BA, but also to a probably unjustified fear of deteriorating ultimate height by giving sex steroids. Yet height prediction in our experience was slightly improved by the addition of androgen therapy. The induction of puberty, therefore, should not be unduly delayed, keeping in mind that an appropriate timing of puberty is most important for optimal socio-sexual integration. Of the patients with gonadotrophin deficiency in our study none had taken up a stable relationship with a sexual partner at the time of final examination at which each one was older than 20 years. This could in part be due to the delay in sexual maturation and could possibly be changed by an earlier induction of puberty.
The overall gain in height by HGH therapy was obvious and estimated to be about'3.4 S.D. in total GHD and 1.9 S.D. in partial GHD. Among the methods of adult height prediction calculated at onset of therapy, the Bayley-Pinneau method mirrors best the height that finally was achieved with therapy. The Tanner method based on BA, on the other hand, was comparable to the extrapolated height and therefore reflects the height that probably would have been attained without therapy. This method gave the highest increase during HGH therapy. Whether these estimations represent actual gain by therapy remains highly speculative and should be analyzed in a greater number of patients. Nevertheless the observation of positive influence by androgen therapy on height prediction (Tanner method based on bone age) is a strong reinforcement to install androgen therapy in the males with gonadotrophin deficiency at a more appropriate age.
